Cargando…

Effect of Glycemic Control During Follow-up on Late Target Lesion Revascularization After Implantation of New-Generation Drug-Eluting Stents in Patients With Diabetes　― A Single-Center Observational Study ―

Background: Few studies have investigated the importance of glycemic control in patients with diabetes mellitus (DM) for reducing the incidence of late target lesion revascularization (TLR) after implantation of new-generation drug-eluting stents (DES). Methods and Results: We retrospectively identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujita, Takanari, Takeda, Teruki, Tsujino, Yasushi, Yamaji, Masayuki, Sakaguchi, Tomoko, Maeda, Keiko, Mabuchi, Hiroshi, Murakami, Tomoyuki, Morimoto, Takeshi, Kimura, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819662/ https://www.ncbi.nlm.nih.gov/pubmed/33693273 http://dx.doi.org/10.1253/circrep.CR-20-0065

Ejemplares similares

Successful Surgery of Right Common Iliac Artery Injury during Lumbar Discectomy with Endovascular Balloon Occlusion of the Aorta Performed by Cardiologists
por: Takashima, Noriyuki, et al.
Publicado: (2019)

Impact of statin therapy on late target lesion revascularization after everolimus-eluting stent implantation according to pre-interventional vessel remodeling and vessel size of treated lesion
por: Asada, Kohei, et al.
Publicado: (2022)

Association of Localized Hypersensitivity and In-Stent Neoatherosclerosis with the Very Late Drug-Eluting Stent Thrombosis
por: Yamaji, Kyohei, et al.
Publicado: (2014)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents
por: Halpern, Michael T, et al.
Publicado: (2004)

Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
por: Zbinden, Rainer, et al.
Publicado: (2016)

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization
por: Piccolo, Raffaele, et al.
Publicado: (2021)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis
por: Zeng, MengYing, et al.
Publicado: (2021)

The stenting strategy of drug-eluting stents for coronary artery disease in patients on dialysis
por: Fujita, Hiroshi, et al.
Publicado: (2014)

An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial
por: Zhang, Haijun, et al.
Publicado: (2019)

Incidence and Clinical Impact of Stent Fracture After the Nobori Biolimus‐Eluting Stent Implantation
por: Kuramitsu, Shoichi, et al.
Publicado: (2014)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease
por: Her, Ae-Young, et al.
Publicado: (2023)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Incidence, Predictors, and Outcomes of Acute and Sub-acute Stent Thrombosis after Emergency Percutaneous Coronary Revascularization with Drug-Eluting Stents: A Prospective Observational Study
por: Kumar, Rajesh, et al.
Publicado: (2022)

Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review
por: Sohail, Mehvish, et al.
Publicado: (2023)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Antibiotic eluting sinus stents
por: Thompson, Harrison M., et al.
Publicado: (2020)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

In-stent restenosis due to delayed healing of abluminal bioresorbable polymer everolimus-eluting stent: insight from histopathological evaluation with directional coronary atherectomy
por: Yamamoto, Hiroyuki, et al.
Publicado: (2021)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial
por: Kuramitsu, Shoichi, et al.
Publicado: (2016)

Coronary stenting: A matter of revascularization
por: Bonaventura, Aldo, et al.
Publicado: (2017)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_73a9a9fskksg4gks67tcrdmg92